Moreover, we found only one common dysfunctional pathway among the five disease groups of serous ovarian tumors: “aryl hydrocarbon receptor binding (GO:0017162),” which is ranked at 42, 2, 2, 29, and 1 in the groups of serous BOTs and serous ovarian carcinomas of stages I–IV, respectively. This evidence concerns the gene AHR and ovarian serous carcinoma.